Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
NCT00003082 · University of Arizona, Other · Completed
Key facts
| NCT number | NCT00003082 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer |
| Official title | A Phase IA Trial of Combined Murine IgG Monoclonal Anti-Transferrin Receptor Antibodies E2.3 and A27.15 in Cancer Patients |
| Lead sponsor | University of Arizona, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | monoclonal antibody A27.15, monoclonal antibody E2.3 |
| Enrollment | 27 |
| Start date | Dec 1, 1997 |
| Primary completion | Feb 1, 2001 |
| Completion | Feb 1, 2001 |
| First posted | Jul 19, 2004 |
| Last update posted | Mar 16, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: